Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions
TC Liu, D Kirn - Cancer research, 2007 - AACR
TC Liu, D Kirn
Cancer research, 2007•AACROncolytic viruses that can destroy cancer cells have been engineered in a variety of ways
with the aim of improving their selectivity and efficacy. Here, we review data from clinical
investigations of these virotherapeutic agents, specifically those that have shown systemic
efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further
directions for optimizing iv delivery and efficacy are discussed.[Cancer Res 2007; 67 (2):
429–32]
with the aim of improving their selectivity and efficacy. Here, we review data from clinical
investigations of these virotherapeutic agents, specifically those that have shown systemic
efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further
directions for optimizing iv delivery and efficacy are discussed.[Cancer Res 2007; 67 (2):
429–32]
Abstract
Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity and efficacy. Here, we review data from clinical investigations of these virotherapeutic agents, specifically those that have shown systemic efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further directions for optimizing i.v. delivery and efficacy are discussed. [Cancer Res 2007;67(2):429–32]
AACR